BioAge Labs, a clinical-stage biotech firm focused on obesity and metabolic disease therapies, aims to raise up to $157.5 million through its initial public offering and private placement, Bloomberg ...

Obesity-focused biotech BioAge Labs said on Wednesday it was seeking a valuation of as much as $587 million in its initial ...

Obesity-focused biotech BioAge Labs said on Wednesday it was seeking a valuation of as much as $587 million in its initial public offering in the United States, according to a regulatory filing.

Obesity drug developer BioAge Labs (BIOA) files for U.S. IPO to offer 7.5M shares at $17-$19 implying valution of up to $602M ...

queue amid a flurry of IPO activity in the sector, with three biotechs listing on the Nasdaq last week – Bicara Therapeutics, ...

BioAge Labs Inc., a clinical-stage biotechnology company developing therapies for obesity and metabolic disease, is seeking ...

Using Crunchbase data, we ranked five of this year’s most heavily funded companies with a female CEO and founder.

The Wall Street firms had a good week, while the reemergence of the ‘megadeal’ this year has buttressed deal work.

Meanwhile, late last week, Bicara Therapeutics set terms for its upcoming IPO. The company, which focuses on transformative ...

MBX Biosciences, which is developing peptide therapies for treating endocrine and metabolic disorders, including obesity, said on Monday it was seeking a valuation of up to $482.5 million in its ...

Paramatrix Technologies IPO subscription status: Paramatrix Technologies' initial public offering (IPO) witnessed a decent subscription overall. Data showed that by 2:30 pm on Friday, the issue ...